<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">Currently there are no approved specific treatments or drugs to treat COVID-19 except the clinical management such as infection prevention, control measures and life supportive care [
 <xref rid="bib48" ref-type="bibr">48</xref>]. The prevailing conditions of current pandemic such as re-emergence of infection cases, uncontrolled transmission and morbidity associated with the disease are crippling the healthcare systems with grave effects on the global economies and posing a challenging situation for health practitioners and scientists to identify the therapeutic strategies to handle this problem [
 <xref rid="bib49" ref-type="bibr">49</xref>]. Therapeutic repurposing of existing drugs like anti-malarials, antivirals, and NSAIDs etc., has been used as an effective approach in management of COVID-19 with drugs inhibiting either the different viral receptors/enzymes or the host cell receptors. Identification of drug targets (viral or host cell) remains one of the important criteria for the discovery of new molecules as well as to check the therapeutic efficacy of existing drug molecules [
 <xref rid="bib13" ref-type="bibr">13</xref>,
 <xref rid="bib50" ref-type="bibr">50</xref>]. The below section briefly enlists the potential therapeutic targets along with the current drugs repurposed towards these targets.
</p>
